Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1741-7015
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease ; volume:10 ; number:1 ; day:8 ; month:11 ; year:2012 ; pages:1-10 ; date:12.2012
BMC medicine ; 10, Heft 1 (8.11.2012), 1-10, 12.2012
- Urheber
-
Bruera, Gemma
- Beteiligte Personen und Organisationen
-
Cannita, Katia
Di Giacomo, Daniela
Lamy, Aude
Troncone, Giancarlo
Dal Mas, Antonella
Coletti, Gino
Frébourg, Thierry
Sabourin, Jean Christophe
Tosi, Mario
Ficorella, Corrado
Ricevuto, Enrico
SpringerLink (Online service)
- DOI
-
10.1186/1741-7015-10-135
- URN
-
urn:nbn:de:1111-2016072946793
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bruera, Gemma
- Cannita, Katia
- Di Giacomo, Daniela
- Lamy, Aude
- Troncone, Giancarlo
- Dal Mas, Antonella
- Coletti, Gino
- Frébourg, Thierry
- Sabourin, Jean Christophe
- Tosi, Mario
- Ficorella, Corrado
- Ricevuto, Enrico
- SpringerLink (Online service)
Ähnliche Objekte (12)
Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer
Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories
Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer
Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories
Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer